First patient has been enrolled in a Phase 1a/b study with Atrogi’s drug candidate ATR-258.

First patient has been enrolled in a Phase 1a/b study with Atrogi’s drug candidate ATR-258.

Our partner Atrogi announces first patient treated with its ATR-258 ß\2\ adrenoceptor agonist in a phase I clinical study for the treatment of type 2 diabetes – a milestone!

For more information, click here.

First patient has been enrolled in a Phase 1a/b study with Atrogi’s drug candidate ATR-258.

You May Also Like

Check out the study “First-in-human study of eliapixant (BAY 1817080), a highly selective P2X3 receptor antagonist: Tolerability, safety and pharmacokinetics.”

Check out the study “Phase I studies of BI 1015550, a preferential phosphodiesterase 4B inhibitor, in healthy males and patients with idiopathic pulmonary fibrosis”

Check out the study “Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment”